Zheijang Neo-Dankon Pharmaceutical Co., Ltd. was established in 2001, located in the state-level Zhejiang southeast chemical raw materials export base-Taizhou city Jiaojiang Park. In 2012, Neo-Dankong achieved powerful combination by introducing new shareholders- Zhejiang Materials Industry Group Corporation (Gloabal Fortune 500). Neo-Dankong was integrated into Zhejiang Materials Industry Chemical Group Co., Ltd and Zhejiang Decision Import and Export Cooperation. LTD. Zhejiang Hongyuan Pharmaceutical Co., Ltd, Lianyungang Hongye Chemical Co., Ltd, Zhejiang Neo-Dankong Pharmaceutical Intemational Co., Ltd, Zhejiang Neo-Dankong biological technology co., LTD, Taizhou City DanKong Veterinary Drug Co., Ltd are subsidiary to it.
It mainly engages in R&D, manufacturing and marketing of pharmaceutical products in the fields such as anti-infection, cardiovascular and nervous system, with Norfloxacin，Atorvastatin, Rosuvastatin,Meropenem,Thiophene and its derivatives and other APIs, intermediates and preparation.Neo-Dankong passed the authentication of GMP, FDA, MHRA, COS, KFDA, etc with several products occupying in the international leading position.
Neo-Dankong Pharmaceutical Co., Ltd is a provincial high-tech enterprise and Provincial Patent model enterprise with a strong R&D team. It established a provincial R & D center and a provincial academician workstation. It set up doctoral scholarship in Chemistry Department and Chemical Engineering Department of Tsinghua University, Peking University, Zhejiang University, University of Science and Technology of China and Nankai University. Meanwhile, Neo-DanKong set up united labs with domestic top universities and scientific research institutes, such as Sichuan Industrial Institute of Antibiotics and Shanghai Institute of Pharmaceutical Industry. Neo-Dankong employed a group of professors and experts to guide R&D, which provided a bridge between industrial capital and intellectual capital. In recent years, Neo-Dankong has obtained 16 invention patents, developed more than 80 new products, some of them filled up the domestic blank, and was included in National Torch Program projects, National Innovation Fund Project and National Key New Product Projects. At present, in order to provide medium-term and long-term sustaining power, So far, Neo-Dankong has established extensively cooperative relationship with many international corporations. Neo-DanKong is enforcing R&D of new drugs for respiratory tract, anti-tumor, etc.
Looking forward to the future, Neo-Dankong will persist in the Core Values “Advance with the times，Create value with clients，Mutual development with staff.”, and persist in Humanistic Spirit “Prioritize morality to maintain the evergreen business; favor wisdom to start business with intelligence and benevolence; value peace to develop harmoniously” Do solid work; continue innovations; try to create an internationally competitive modern pharmaceutical enterprise. Serve customer, repay society; contribute to world.
Zheijang Neo-Dankon Pharmaceutical Co., Ltd.